Attentional Capture by Real-life Episodic Information (EPICAPTURE)

Attention facilitates the allocation of processing resources and the control of behavior among competing stimuli. Current research focuses primarily on attention control networks in the dorsal frontoparietal (DAN) and ventral (VAN) cortex. However, typical laboratory experiments emphasize task-specific processing, neglecting the possible role of memory. Although a few studies have examined the contribution of memory to attention control, they have generally used simple tasks in the laboratory. These tasks are unlikely to produce true traces of episodic memory, which are - by definition - characterized by complex contextual information (what, where, when) and personal relevance. This research will therefore use an innovative protocol based on mobile phone technology to generate episodes in the participants' real lives and then measure the impact of these past personal experiences on attention allocation (by assessing eye movements) and on the activity of the DAN/VAN system (using functional imaging).

The main hypothesis of the study is that knowledge acquired during everyday life contributes to the subsequent allocation of processing resources, via engagement of the DAN/VAN attention systems.

Study Overview

• Status: Not yet recruiting
• Conditions: Healthy Volunteers; Attentional Capture
• Intervention / Treatment: Behavioral: Old vs new objects" encoding phase and fMRI; Behavioral: " incongruent vs. congruent contexts " encoding phase and fMRI

• Study Type: Interventional
• Enrollment (Estimated): 86
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Emiliano Macaluso, Pr; Phone Number: +33 04 72 91 34 07; Email: emiliano.macaluso@univ-lyon1.fr
• Study Contact Backup: Name: Samy Adrian FOUDIL; Phone Number: +33 07 77 36 37 68; Email: samy@samalgo.com

Study Locations

• France
  • Rhone
    • Bron, Rhone, France, 69500
      • UCBL1, CRNL Inserm U1028, CNRS UMR5292, équipe IMPACT
      • Contact: Emiliano Macaluso, Pr; Phone Number: +33 04 72 91 34 07; Email: emiliano.macaluso@univ-lyon1.fr
      • Contact: Samy adraim FOUDIL; Phone Number: +33 07 77 36 37 68; Email: samy@samalgo.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Be 18 years old to 40 years old
• Be right-handed
• Do not wear glasses
• Have a mobile-phone compatible with the application, minimum 6rd generation Android operating system, with geo-localization activated and accepted by the user
• Undertake to comply with the instructions and recommendations for MRI examination
• Provide informed written consent to participate in the study

Exclusion Criteria:

• History of known neurological or psychiatric illness
• Cognitive problems limiting the understanding of instructions
• Recent taking psychotropic drugs (antidepressants, anxiolytics, antipsychotics). The main treatments not authorized during this research are the following: Psychotropic treatments (drugs that can induce changes in perception, sensation, mood, consciousness or behavior). Like what:
• Antipsychotics (valproic acid, amisulpride, aripiprazole, clozapine, cyamemazin, haloperidol, loxapine, olanzapine, risperidone).
• Antidepressants (Amitriptyline, Citalopram, Clomipramine, Duloxetine, Escitalopam, Fluoxetine, Mianserine, Mirtazapine, Nortriptyline, Paroxetine, Sertraline, Venlafaxine).
• Anxyolitics
• Pregnant or breastfeeding women
• Persons deprived of their liberty by a judicial or administrative decision
• Persons admitted to a health or social institution for purposes other than research
• Adults subject to a legal protection measure (guardianship, curatorship)
• Persons not affiliated to a social security scheme or beneficiaries of a similar scheme
• Participation in another research study of the current study
• Contraindication for fMRI scanning

• Participant not agreeing to be informed in the event of the incidental discovery of an anomaly on MRI

  • For visit number 2 :

• Alcohol consumption (> 3 drinks) in the 24h before the experiment
• Alcohol consumption the day of the experiment
• Cafeine consumption 1 hour or less before the experiment
• Drug consumption within the 24h preceding the experiment
• Antimalarial treatment within the 3 days preceding the experiment

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Old vs new objects; The following week after the "Old vs new objects" encoding phase of 3 weeks, participants will have an fMRI. During fMRI, participants will see objects already seen or not seen during the encoding phase.	Behavioral: Old vs new objects" encoding phase and fMRI; During the encoding phase, a set of 60 objects will be presented to the participants in their everyday life. Pictures of objects sent to their app mobile phone over a period of 3 weeks. The following week, participants will have an fMRI. During fMRI, participants will see objects already seen or not seen during the encoding phase.
Experimental: incongruent vs. congruent contexts; The following week after the "incongruent vs. congruent contexts" encoding phase of 3 weeks, participants will have an fMRI. During fMRI, participants will see objects encoding in congruent or incongruent contexts.	Behavioral: " incongruent vs. congruent contexts " encoding phase and fMRI; During the encoding phase, a set of 60 objects will be presented to the participants in their everyday life. Pictures of objects sent to their app mobile phone over a period of 3 weeks. This time, the objects will be chosen according to the participant's location. The following week, participants will have an fMRI. During fMRI, participants will see objects encoding in congruent/incongruent contexts.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
activation pattern in fMRI: "old vs. new" objects (intervention 1)	activation pattern in DAN/VAN system in fMRI experiments for the comparison of trials with gaze directed towards "seen/old vs. unseen/new" objects.	One time during the week after the 3 weeks encoding phase

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
activation pattern in fMRI: "place" images in intervention 1	activation pattern in DAN/VAN system in fMRI experiments when participants direct gaze towards the image depicting the location where they were at the time they received an object during the encoding phase, compared with trials when gaze is directed towards the image of a place that was not visited during the encoding phase.	One time during the week after the 3 weeks encoding phase
activation pattern in fMRI: incongruent vs. congruent contexts (intervention 2)	activation pattern in DAN/VAN system in fMRI experiments for the comparison of trials with gaze directed towards old/seen objects encoded in incongruent vs congruent contexts.	One time during the week after the 3 weeks encoding phase

Collaborators and Investigators

• Sponsor: Hospices Civils de Lyon

Study record dates

Study Major Dates

• Study Start (Estimated): December 15, 2025
• Primary Completion (Estimated): January 15, 2029
• Study Completion (Estimated): January 15, 2029

Study Registration Dates

• First Submitted: April 11, 2025
• First Submitted That Met QC Criteria: April 11, 2025
• First Posted (Actual): April 18, 2025

Study Record Updates

• Last Update Posted (Actual): April 18, 2025
• Last Update Submitted That Met QC Criteria: April 11, 2025
• Last Verified: April 1, 2025

More Information

Terms related to this study

• Keywords: Healthy volunteers; Attentional capture; real-life episodic information
• Other Study ID Numbers: 69HCL25_0108

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No